

UNITED STATES DEPARTMENT OF COMMERCE

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231	
Washington, D.O. Edeor	\mathcal{O}

APPLICATION NO.	FILING DATE	FIRST NAMED INVE	NTOR		ATTORNEY DOCKET NO.
09/053,871	04/01/98	PINSKY		D	51917-B
-		HM12/0527			EXAMINER
COOPER AND DUNHAM				GAMBEL,	P
JOHN P WHITE		OTOAG	<u> </u>	ART UNIT	PAPER NUMBER
1185 AVENUE NEW YORK NY		ZTPW9	-	1644	3

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

DATE MAILED: 05/27/99



Office Action Summary

Application No.

99/053871

Examiner

Group Art Unit

GAMSEL

(GUY

	GamBEL	1644
The MAILING DATE of this communication appears	on the cover sheet beneath	the correspondence address
Period for Response		
A SHORTENED STATUTORY PERIOD FOR RESPONSE IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE	MONTH(S) FROM THE
 Extensions of time may be available under the provisions of 37 CFR 1.13 from the mailing date of this communication. If the period for response specified above is less than thirty (30) days, a ref NO period for response is specified above, such period shall, by defaul Failure to respond within the set or extended period for response will, by 	response within the statutory minimit, expire SIX (6) MONTHS from the	um of thirty (30) days will be considered timely. mailing date of this communication.
Status		
☐ Responsive to communication(s) filed on		
☐ This action is FINAL.		
 Since this application is in condition for allowance except for accordance with the practice under Ex parte Quayle, 1935 C 		as to the merits is closed in
Disposition of Claims		
「Claim(s)	i	s/are pending in the application.
Of the above claim(s)		
☐ Claim(s)	i	s/are allowed.
□ Claim(s)	i	s/are rejected.
Claim(a)		•
. 21		are subject to restriction or election
		requirement.
Application Papers		
☐ See the attached Notice of Draftsperson's Patent Drawing F	·	
☐ The proposed drawing correction, filed on	i i	proved.
☐ The drawing(s) filed on is/are objected	i to by the Examiner.	
 The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. 		
• •		
Priority under 35 U.S.C. § 119 (a)-(d)		
 □ Acknowledgment is made of a claim for foreign priority unde □ All □ Some* □ None of the CERTIFIED copies of the □ received. □ received in Application No. (Series Code/Serial Number) 	priority documents have beer	
☐ received in this national stage application from the International		
*Certified copies not received:		
Attachment(s)		
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s	s) 🗆 Interview	Summary, PTO-413
☐ Notice of References Cited, PTO-892	Informal Patent Application, PTO-152	
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948		······································
Office A	ction Summary	

U. S. Patent and Trademark Office PTO-326 (Rev. 3-97) Serial No. 09/053871 Art Unit 1644

DETAILED ACTION

- 1. The location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1644, Group 1640, Technology Center 1600.
- 2. Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-305-3704. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Paula Hutzell, Ph.D., Supervisory Patent Examiner at Paula.Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.
- 3. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
- I. Claims 1-20, 25-28, drawn to methods for treating ischemic-reperfusion conditions with Factor IXa compounds, classified in Class 424, subclass, 130.1 and Class 514, subclass 8 or 44.
- II. Claims 21-24, drawn to methods of identifying compounds that are capable of improving ischemic disorders, classified in Class 51, subclass 8.
- III. Claims 29-30, drawn to methods of inhibiting clot formation with muteins, classified in Class 514 subclass 8.
- IV. Claims 31-32, drawn to methods of monitoring the effects of Factor IXa on ischemic disorders, classified in Class 600, subclass 407.
- 4. Inventions I/II/III/IV are different methods requiring different reagents, methods steps and endpoints. Therefore they are patentably distinct.
- 5. Because these inventions are distinct for the reasons given above and the search required for any group from Groups I-IV is not required for any other group from Groups I-IV and Groups I-IV have acquired a separate status in the art as shown since the searches are not co-extensive and encompass divergent subject matter, restriction for examination purposes as indicated is proper.
- 6. This application contains claims directed to the following patentably distinct species of the claimed Groups I/II/III/IV: wherein the Factor IX compound is:
 - A) a peptide or a mutated peptide,
 - B) a peptiodomimetic,
 - C) a nucleic acid or a mutated nucleic acid,
 - D) a small molecule,
 - E) a mutein or
 - F) an antibody or fragment thereof.

These species are distinct because their structures and modes of action are different.

Serial No. 09/053871 Art Unit 1644

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 21, 29 and 31 are generic.

7. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

- 8. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Phillip Gambel, PhD.
Patent Examiner
Group 1640
Technology Center 1600
May 24, 1999

PHILLIP GAMBEL